ArticleEJNMMI research2018
Bone marrow cell homing to sites of acute tibial fracture:
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Trial
- Deer antler polypeptides promote osteogenesis for fracture healing via activating neurosensory PGE2/EP4/p-CREB axis.Journal of orthopaedic translation · 2026Article
- In Vivo Positron Emission Particle Tracking (PEPT) of Single Cells Using an Expectation Maximization Algorithm.IEEE transactions on medical imaging · 2026Article
- In vivo tracking of ex-vivo-generatedMolecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling withJournal of translational medicine · 2023Article
- Implant Imaging: Perspectives of Nuclear Imaging in Implant, Biomaterial, and Stem Cell Research.Bioengineering (Basel, Switzerland) · 2023Review
- Characterization of Chimeric Antigen Receptor Modified T Cells Expressing scFv-IL-13Rα2 after Radiolabeling with 89Zirconium Oxine for PET Imaging.Research square · 2023Article
- Evaluation of differentScientific reports · 2022Article
- Direct Cell Radiolabeling forChemical reviews · 2022Review
- Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation.Molecular imaging and biology · 2022Review
- Biodistribution studies for cell therapy products: Current status and issues.Regenerative therapy · 2021Review
- In Vivo PET Imaging of Monocytes Labeled with [Cancers · 2021Article
- Microarray Analysis of Differential Gene Expression Between Traumatic Temporomandibular Joint Fibrous and Bony Ankylosis in a Sheep Model.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Spatio-temporal biodistribution ofScientific reports · 2021Article
- Adiponectin signalling in bone homeostasis, with age and in disease.Bone research · 2021Review
- Imaging of cell-based therapy usingNanotheranostics · 2021Review
- Lung delivery of MSCs expressing anti-cancer protein TRAIL visualised withStem cell research & therapy · 2020Article
- Evidence of Accumulated Endothelial Progenitor Cells in the Lungs of Rats with Pulmonary Arterial Hypertension byMolecular therapy. Methods & clinical development · 2020Article
- Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Reproducibility of GMP-compliant production of therapeutic stressed peripheral blood mononuclear cell-derived secretomes, a novel class of biological medicinal products.Stem cell research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundBone fracture healing is dependent upon the rapid migration and engraftment of bone marrow (BM) progenitor and stem cells to the site of injury. Stromal cell-derived factor-1 plays a crucial role in recruiting BM cells expressing its receptor CXCR4. Recently, a CXCR4 antagonist, plerixafor, has been used to mobilize BM cells into the blood in efforts to enhance cell migration to sites of injury presumably improving healing. In this study, we employed zirconium-89 (
resultsIn d0- and d1-fracture groups, 0.7% and 1.7% of administered BM cells accumulated within the fracture, respectively. Plerixafor treatment reduced BM cell migration to the fracture by approximately one-third (p < 0.05 for both fracture groups). Flow cytometry analysis of donor cells collected from the injured site revealed a predominance of CD45
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.